CD44 and prostate carcinoma: A non-malignant cell line RWPE-1 as well as prostate cancers PC-3 and DU145 demonstrated the CD44+/CD24- and CD44+/CD24+ phenotypes of progenitor cells, while prostate cancers 22Rv1 and LNCaP demonstrated CD44-/CD24- and CD44-/CD24+ phenotypes.